Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II XELOX + trastuzumab as perioperative treatment in resectable gastric or gastroesophageal junction adenocarcinoma
2009-017848-14Phase 2Completed
- Sponsor
- Roche Farma, S.A.
- Start
- Jan 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab, capecitabine and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Roche Farma, S.A. Primary endpoint: Disease-free survival at 18 months. Started Jan 2010; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2009-017848-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017848-14.